Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
基本信息
- 批准号:10384796
- 负责人:
- 金额:$ 100.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-06 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimalsBenchmarkingBiotechnologyBuffaloesCancerousCanis familiarisCharacteristicsChronic viral hepatitisClinicClinicalClinical ResearchComputer ModelsDataDoseDoxorubicinElementsEncapsulatedExperimental Animal ModelFormulationFutureGoalsHepatitis BHumanIn complete remissionLasersLicensingLightLightingLipidsLiposomesLiver neoplasmsLocally Advanced Malignant NeoplasmMagnetic Resonance ImagingMalignant neoplasm of liverMaximum Tolerated DoseMeasuresMethodsModelingMonitorMusNatureOryctolagus cuniculusPUVA PhotochemotherapyPatientsPersonsPharmaceutical PreparationsPhasePhospholipidsPhototherapyPilot ProjectsPorphyrinsPrimary NeoplasmPrimary carcinoma of the liver cellsRattusReportingRodentRouteSafetySerumSmall Business Technology Transfer ResearchSurfaceSurvival RateTestingTherapeuticTissuesToxic effectToxicologyTranslatingVaccinesVascular PermeabilitiesWoodchuckWorkabsorptionbaseblood perfusioncontrast enhanceddosimetryfirst-in-humaninterstitiallight dosimetryliver cancer patientmeetingsnanoparticulatenovelnovel therapeuticsprimary endpointresponsesecondary endpointsuccesstreatment planningtumortumor ablation
项目摘要
Summary
Our goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally
advanced liver cancers. Doxorubicin (Dox) can be actively loaded into long circulating, serum-stable, porphyrin-
phospholipid (PoP) liposomes and be released with 665-nm laser light (PhotoDox). This approach leads to vastly
enhanced drug accumulation in irradiated tissues, resulting in ultrapotent tumor ablation. In the phase I STTR,
we employed this dosimetry-treatment planning platform to guide light administration of I-CPT with PhotoDox.
We demonstrated that this treatment planning with light dosimetry is effective in ablating large orthotopic
hepatocellular carcinoma tumors in rats. In this phase II STTR application we propose to further advance I-CPT
with PhotoDox towards an IND for enabling future clinical studies. To that end we propose to complete the
following aims: Aim 1: Optimizing I-CPT with PhotoDox for a durable complete response of large spontaneous
hepatocellular carcinoma in a woodchuck model. The woodchuck model is the largest experimental animal model
with spontaneous locally advanced hepatocellular carcinoma (HCC) in the context of chronic viral hepatitis and
liver cancer, as seen in people with hepatitis B. In pilot studies, we have safely dosed PhotoDox to woodchucks,
confirmed the characteristic long-circulating nature of PhotoDox and applied the FEM based treatment planning
and dosimetry to safely treat HCC (~50 cm3) with I-CPT in woodchucks. We will address the key question: What
are the optimal light settings for I-CPT with PhotoDox in the treatment of large HCC? Aim 2: Generate IND-
enabling data on the toxicity of I-CPT with PhotoDox. POP BIO has previously generated non-GLP toxicity data
of PhotoDox in rats including cursory establishment of the maximum tolerated dose. Since then, POP BIO has
held a pre-IND meeting with the FDA, who confirmed the suitability of the 505(b)(2) route for components of
PhotoDox and provided guidance about the required toxicological studies required prior to first-in-human studies.
We will address the key question: What is the toxicity of PhotoDox under GLP studies? This translational Phase
II project will provide required data for an IND submission to the FDA by providing valuable relevant to
understanding I-CPT treatment in the context of human liver cancer patients. If successful, I-CPT with PhotoDox
stands to benefit the majority of new liver cancer patients, who have inoperable and problematic primary tumors.
总结
我们的目标是商业化间质化学光疗(I-CPT)作为一种新的治疗选择,
晚期肝癌多柔比星(Dox)可以主动装载到长循环的、血清稳定的卟啉受体中。
脂质体中,并且用665-nm激光(PhotoDox)释放。这种方法导致了巨大的
增强的药物在照射组织中的积累,导致超强效肿瘤消融。在第一阶段STTR中,
我们采用该剂量测定-治疗计划平台来指导I-CPT与PhotoDox的光管理。
我们证明,这种治疗计划与光剂量是有效的消融大原位
大鼠肝癌肿瘤。在第二阶段STTR应用中,我们建议进一步推进I-CPT
与PhotoDox一起申请IND,以实现未来的临床研究。为此,我们建议完成
目的1:优化I-CPT与PhotoDox,以获得大的自发性
土拨鼠模型中的肝细胞癌。土拨鼠模型是最大的实验动物模型
慢性病毒性肝炎背景下的自发性局部晚期肝细胞癌(HCC),
肝癌,见于B型肝炎患者。在试点研究中,我们已经安全地给土拨鼠服用了PhotoDox,
证实了PhotoDox的特征性长循环性质,并应用了基于FEM的治疗计划
和剂量测定,以安全地治疗土拨鼠肝癌(~50立方厘米)与I-CPT。我们将解决关键问题:什么
I-CPT联合PhotoDox治疗大肝癌的最佳光照设置是什么?目标2:生成IND-
使I-CPT与PhotoDox的毒性数据成为可能。POP BIO之前已生成非GLP毒性数据
包括粗略确定最大耐受剂量。从那时起,POP BIO
与FDA举行了IND前会议,FDA确认了505(B)(2)途径对成分的适用性
PhotoDox,并提供了关于首次人体研究之前所需毒理学研究的指南。
我们将解决关键问题:GLP研究中PhotoDox的毒性是什么?这个转化阶段
II项目将通过提供以下有价值的相关信息,为向FDA提交IND申请提供所需数据:
了解I-CPT治疗人类肝癌患者的背景。如果成功,I-CPT与PhotoDox
这将使大多数新的肝癌患者受益,他们患有无法手术和有问题的原发性肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GAL SHAFIRSTEIN其他文献
GAL SHAFIRSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GAL SHAFIRSTEIN', 18)}}的其他基金
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy
用于钌基光敏剂介导的术中光动力治疗的光学表面照射器光剂量测定
- 批准号:
10303270 - 财政年份:2021
- 资助金额:
$ 100.14万 - 项目类别:
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic Therapy
用于钌基光敏剂介导的术中光动力治疗的光学表面照射器光剂量测定
- 批准号:
10454364 - 财政年份:2021
- 资助金额:
$ 100.14万 - 项目类别:
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
- 批准号:
10700814 - 财政年份:2020
- 资助金额:
$ 100.14万 - 项目类别:
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
光激活纳米颗粒阿霉素间质化学光疗
- 批准号:
10010747 - 财政年份:2020
- 资助金额:
$ 100.14万 - 项目类别:
Integrated Image-Guided Dosimetry and Treatment Planning for Photodynamic Therapy
光动力治疗的集成图像引导剂量测定和治疗计划
- 批准号:
9187830 - 财政年份:2015
- 资助金额:
$ 100.14万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 100.14万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 100.14万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 100.14万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 100.14万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 100.14万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)